After months of rumors, Google introduced its personal smartwatch, referred to as the Pixel Watch, shall be coming this fall.
Though the tech big has supported smartwatches via its wearable working system and completed its acquisition of Fitbit final 12 months, this is Google’s first branded smartwatch. The Pixel Watch may have a round, domed design made with recycled stainless-steel and customizable bands.
Regardless that the watch additionally has loads of options not involved with health monitoring, Rick Osterloh, Google’s senior vp of gadgets and companies, teased the Pixel Watch’s “deep integration” with Fitbit that can embrace coronary heart charge and sleep monitoring in addition to exercise metrics customers can measure in opposition to their targets.
In the meantime, Google is coming into a crowded marketplace for health-tracking wearables, with opponents like Apple, Amazon, Samsung, Withings and Garmin. Fitbit not too long ago landed FDA clearance for its long-awaited photoplethysmography atrial fibrillation (AFib) detection algorithm.
The chatbot gives cognitive behavioral remedy that would reduce despair and nervousness signs and assist customers handle ache to enhance bodily perform.
The Breakthrough Gadgets program permits firms to work with the FDA earlier than advertising approval. It goals to hurry the event, evaluation and evaluate course of for medical gadgets and mixture merchandise that would present higher therapy for individuals with debilitating or life-threatening diseases or circumstances.
“We’re thrilled to realize this significant designation from the FDA and look ahead to working intently with the company to proceed growth of AI-based cognitive behavioral remedy,” Wysa cofounder and CEO Jo Aggarwal stated in a press release.
“Our mission is to assist these in want of help with an all the time accessible platform, and throughout these difficult occasions it’s more essential than ever to offer psychological health choices.”
Wysa raised $5.5 million in Series A funding in Might 2021.
Pear Therapeutics is increasing a program to supply its prescription digital therapeutics via partnerships with telehealth suppliers.
The corporate’s latest accomplice, QuickMD, will be capable of present eligible sufferers with Pear’s opioid use dysfunction product, reSET-O.
In April, the corporate announced the program with its first telehealth providing, addition medicine-focused PursueCare.
“Pear is happy to work with telehealth suppliers in offering revolutionary, FDA-authorized therapies that allow round the clock entry to help eligible sufferers of their restoration journey throughout these troublesome occasions,” Chief Business Officer Julia Strandberg stated in a press release. “After so many unsure months, it is very important meet individuals the place they’re and the place they really feel comfy, offering them with entry to the care they want.”